Condition 101 About Macroamylasemia

What is the definition of Macroamylasemia?

Macroamylasemia is the presence of an abnormal substance called macroamylase in the blood.

What are the causes for Macroamylasemia?

Macroamylase is a substance that consists of an enzyme, called amylase, attached to a protein. Because it is large, macroamylase is filtered very slowly from the blood by the kidneys.

Most people with macroamylasemia do not have a serious disease that is causing it, but the condition has been associated with:

  • Celiac disease
  • Lymphoma
  • HIV infection
  • Monoclonal gammopathy
  • Rheumatoid arthritis
  • Ulcerative colitis

What are the symptoms for Macroamylasemia?

Macroamylasemia does not cause symptoms.

REFERENCES

Frasca JD, Velez MJ. Acute pancreatitis. In: Parsons PE, Wiener-Kronish JP, Stapleton RD, Berra L, eds. Critical Care Secrets. 6th ed. Philadelphia, PA: Elsevier; 2019:chap 52.

Siddiqi HA, Salwen MJ, Shaikh MF, Bowne WB. Laboratory diagnosis of gastrointestinal and pancreatic disorders. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 23rd ed. St Louis, MO: Elsevier; 2017:chap 22.

Tenner S, Steinberg WM. Acute pancreatitis. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. 10th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 58.

Latest Advances On Macroamylasemia

  • Condition: Pancreatitis after Endoscopic Retrograde Cholangiopancreatography
  • Journal: Annals of palliative medicine
  • Treatment Used: Rectal Indomethacin plus Nitroglycerin
  • Number of Patients: 526
  • Published —
This study tested the safety and efficacy of using rectal indomethacin plus nitroglycerin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography.

Clinical Trials For Macroamylasemia

Clinical Trial
  • Status: Active, not recruiting
  • Phase: N/A
  • Intervention Type: Drug, Device
  • Participants: 800
  • Start Date: October 15, 2019
7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients: a Multicentre, Single-blinded, Randomised Controlled Trial